Close

Amgen To Present At The Credit Suisse 25th Annual Healthcare Conference

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Upperton completes build of new £7m sterile manufacturing facility

Nottingham - Leading UK contract development and manufacturing organisation (CDMO)...

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

2025 AI Trends & Pharma Predictions

As we navigate what the future of healthcare will...

Amgen will present at the Credit Suisse 25th Annual Healthcare Conference at 9 a.m. MT on Tuesday, Nov. 8, 2016, in Scottsdale, Ariz. David W. Meline, executive vice president and chief financial officer at Amgen, and Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will present at the conference.

Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.For more information, visit www.amgen.com.

CONTACT: Amgen,
Thousand Oaks
Kristen Davis,
805-447-3008 (media)

Kristen Neese,
805-313-8267 (media)

Arvind Sood,
805-447-1060 (investors)

Latest stories